Agenus to Present at the 2021 ASCO Annual Meeting
April 28 2021 - 5:30PM
Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive
pipeline of checkpoint antibodies, cell therapies, adjuvants, and
vaccines designed to activate immune response to cancers and
infections, today announced that it will give two presentations at
the 2021 American Society for Clinical Oncology (ASCO) Annual
Meeting poster sessions. The ASCO meeting will be held from June 4
– 8, 2021.
Presentation Details:
Abstract title: Differentiated activity profile
for the PD-1 inhibitor balstilimabAbstract number:
5529Poster Session: Gynecologic
CancerPresenting author: Cailin Joyce, PhD
Abstract title: Initial findings of the
first-in-human Phase I study of AGEN2373, a conditionally active
CD137 agonist antibody, in patients (pts) with advanced solid
tumors Abstract number: 2634Poster
Session: Developmental Therapeutics -
ImmunotherapyPresenting author: Anthony Tolcher,
MD
Full abstracts will be released on Wednesday, May 19. The 2021
ASCO Annual Meeting will take place virtually on June 4 – 8,
2021.
About balstilimabBalstilimab is a novel, fully
human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1
(programmed cell death protein 1) from interacting with its ligands
PD-L1 and PD-L2. PD-1 is a negative regulator of immune activation
that is considered a foundational target within the immuno-oncology
market. Balstilimab is currently in clinical trials as monotherapy
and in combination with Agenus’ anti-CTLA-4, zalifrelimab, in an
ongoing Phase 2 study for recurrent/metastatic cervical cancer.
A Biologics License Application has been submitted to the U.S.
Food and Drug Administration for the use of balstilimab to treat
recurrent/metastatic cervical cancer.
About AGEN2373AGEN2373 is a novel, fully human
monoclonal conditionally active CD137 agonist antibody designed to
selectively enhance CD137 co-stimulatory signaling in activated
immune cells while mitigating side effects associated with systemic
activation of CD137. CD137 (4-1BB) is a positive regulator of the
immune system that is highly upregulated on activated T cells
(adaptive immune cells) and NK cells (innate immune cells).
AGEN2373 is advancing in a Phase 1 clinical trial against solid
tumors.
About AgenusAgenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer. The
Company's vision is to expand the patient populations benefiting
from cancer immunotherapy by pursuing combination approaches that
leverage a broad repertoire of antibody therapeutics, adoptive cell
therapies (through its AgenTus Therapeutics subsidiary), and
proprietary cancer vaccine platforms. The Company is equipped with
a suite of antibody discovery platforms and a state-of-the-art GMP
manufacturing facility with the capacity to support clinical
programs. Agenus is headquartered in Lexington, MA. For more
information, please visit www.agenusbio.com and our Twitter handle
@agenus_bio. Information that may be important to investors will be
routinely posted on our website and Twitter.
Forward-Looking StatementsThis press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions of the federal securities laws, including
statements regarding the therapeutic potential of balstilimab, an
anti-PD-1, and AGEN2373. These forward-looking statements are
subject to risks and uncertainties that could cause actual results
to differ materially. These risks and uncertainties include, among
others, the factors described under the Risk Factors section of our
most recent Quarterly Report on Form 10-Q or Annual Report on Form
10-K filed with the Securities and Exchange Commission. Agenus
cautions investors not to place considerable reliance on the
forward-looking statements contained in this release. These
statements speak only as of the date of this press release, and
Agenus undertakes no obligation to update or revise the statements,
other than to the extent required by law. All forward-looking
statements are expressly qualified in their entirety by this
cautionary statement.
ContactAgenus Investor
RelationsJan Medina,
CFAAgenus781-674-4490Jan.Medina@agenusbio.com
Agenus Media RelationsKimberly HaKKH
Advisors917-291-5744kimberly.ha@kkhadvisors.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024